The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Real-world Outcomes of Hepatitis C Treatment during the Interferon-free Era at an Urban Safety-net Hospital
Assoumou SA, Huang W, Young K, Horsburgh CR, Linas BP. J Health Care Poor Underserved. 2017;28(4):1333-1344. doi: 10.1353/hpu.2017.0118.
Abstract
BACKGROUND:
Little is known about real-world outcomes for new interferon-free treatment for hepatitis C virus (HCV) among underserved and diverse communities.
OBJECTIVE:
To identify predictors of treatment prescription and evaluate outcomes as measured by sustained virologic response (SVR) with HCV RNA testing three months after therapy completion.
DESIGN:
Retrospective cohort at a safety-net health care system.
PARTICIPANTS:
Patients with (1) at least one clinical visit between December 6, 2013, and December 31st 2014; and (2) at least three months follow-up.
KEY RESULTS:
Predominantly non-White cohort (61%). Of 1,284 HCV-infected patients 121 prescribed sofosbuvir-based therapy. Severe liver fibrosis (OR 1.66, 95% CI 1.05, 2.64) independently associated with treatment prescription. In those with evaluable HCV RNA, SVR was 99%.
CONCLUSION:
Cure rates similar to clinical trial data can be achieved in diverse underserved communities.